Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 10.4% in the morning session after the company announced it received U.S. Food and Drug Administration (FDA) approval for ...

Amphastar Pharmaceuticals (NASDAQ:AMPH) saw its stock increase by 4% after the company announced that the FDA had approved ...

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to ...

Investing.com -- Amphastar Pharmaceuticals (NASDAQ: AMPH) stock gained 4% after the company announced FDA approval for its generic version of iron sucrose injection, a treatment for iron deficiency ...

Pipeline Regulatory Progress -- Two risk-adjusted product launches (AMP-002 and AMP-015) are included in the flat full-year ...

Amphastar is undervalued (~71% upside), but lacks an economic moat and faces modest growth, so I favor a cautious gradual ...

On a per-share basis, the Rancho Cucamonga, California-based company said it had profit of 64 cents. Earnings, adjusted for one-time gains and costs, were 85 cents per share. The results exceeded Wall ...

Amphastar's strong first quarter results were led by BAQSIMI revenue growth of 22% over what Eli Lilly & Company ("Lilly") reported for the first quarter of 2023.

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer® for the treatment of iron deficiency anemia in patients with chro ...

Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Greetings, and welcome to the Amphastar Pharmaceuticals’ Second ...